Virax Biolabs CFO Jason Davis files Form 3

Virax Biolabs Group Ltd filed an initial insider ownership report for Chief Financial Officer Jason Davis on Form 3.

Accepted by SEC EDGAR 03/18/2026 - 04:05 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Virax Biolabs Group Ltd filed an initial insider ownership report for Chief Financial Officer Jason Davis on Form 3. This filing serves as a baseline disclosure of his beneficial ownership position when he became a reporting insider. The data provided does not list any specific shareholdings or report any buy, sell, or option exercise transactions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Jason Davis’s Form 3 filing for Virax Biolabs (VRAX) show?

The Form 3 filing for CFO Jason Davis establishes his status as an insider at Virax Biolabs Group Ltd. In the data provided, it does not list any specific holdings or report any purchases, sales, or option exercises.

Does the Virax Biolabs (VRAX) Form 3 indicate Jason Davis bought or sold shares?

No transactions are reported in the Form 3 data for Jason Davis. The transaction summary shows zero buys, sells, exercises, gifts, or other movements, indicating this filing is purely an initial ownership baseline.

Why is a Form 3 important for Virax Biolabs (VRAX) insiders?

Form 3 is the initial beneficial ownership statement for company insiders. It creates a reference point for future Form 4 and Form 5 filings, helping investors track later share purchases, sales, or option exercises by the insider over time.

Is there any trading signal from Jason Davis’s Form 3 at Virax Biolabs (VRAX)?

The provided Form 3 data does not show any trades by Jason Davis. With no reported purchases, sales, or derivative exercises, this filing carries no trading signal and functions only as an administrative ownership disclosure.

What role does Jason Davis hold at Virax Biolabs (VRAX) in this Form 3?

In the Form 3, Jason Davis is identified as an officer of Virax Biolabs Group Ltd, serving as Chief Financial Officer. This role qualifies him as an insider who must report equity ownership and future changes in that ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Davis Jason

(Last) (First) (Middle)

BIOCITY GLASGOW BO'NESS ROAD

NEWHOUSE LANARKSHIRE

(Street)

MOTHERWELL LANARKSHIRE ML1 5UH

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Virax Biolabs Group Ltd [ VRAX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Jason Davis	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)